Eczema Therapeutics Market to Surpass US$ 32,347.7 Million by 2028

Global Eczema Therapeutics Market, by Treatment (Corticosteroids, Emollients/Moisturizers, Antihistamines, Calcineurin inhibitors, Antibiotics, Immunomodulators, and Interleukin inhibitors), by Distribution Channel (Hospital and Clinics, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 15,453.4 million in 2021 and is expected to exhibit a CAGR of 11.1% during the forecast period (2021-2028).

Market players are indulged in receiving drug approvals from the regulatory authorities for the treatment of eczema, which is expected to increase the growth of the global eczema therapeutics market over the forecast period. For instance, in 2017, Regeneron, received approval from the U.S. Food and Drug Administration (U.S. FDA) for Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or for those patients for whom topical therapies are not advisable. Dupixent can be used with or without topical corticosteroids.

Increasing research and development activities by the market players and research institutes is expected to drive the growth of the global eczema therapeutics market over the forecast period. For instance, on February 24, 2021, researchers from the University of California, San Diego (UCSD), School of Medicine, reported that they have identified a universal strain of bacteria i.e. Staphylococcus hominis A9, which is derived from healthy human skin that can treat atopic dermatitis. Staphylococcus aureus usually colonizes patients with atopic dermatitis and makes the disease worse by promoting inflammation. The current study is focusing on evaluating the safety and the mechanisms of action of Staphylococcus hominis A9 (ShA9), as a topical therapy for atopic dermatitis.

Global Eczema Therapeutics Market- Impact of Coronavirus (COVID – 19) Pandemic

The coronavirus disease (COVID-19) pandemic is expected to drive growth of the global eczema therapeutics market over the forecast period. COVID-19 is the recent pandemic outbreak which was first reported on December 31, 2019 in Wuhan, China. The World Health Organization declared coronavirus disease (COVID-19) as a pandemic on March 11, 2020. According to the World Health Organization (WHO) Weekly epidemiological update on COVID-19, the number of new cases and deaths continued to decrease, with nearly 3 million new cases of COVID-19 were reported globally and with just under 56 000 new deaths till July 13, 2021.

Increasing research and development activities by the government organizations is expected to increase the growth of the global eczema therapeutics market over the forecast period. For instance, on April 29, 2021, European Medicines Agencies conducted a clinical trial in order to evaluate the usage of Olumiant (baricitinib) for the treatment of COVID-19 in hospitalized patients of age 10 who required supplemental oxygen. Olumiant is an immunosuppressant (a medicine that reduces the activity of the immune system). It is currently authorized for use in adults with moderate to severe rheumatoid arthritis or atopic dermatitis (eczema).

 Browse 39 Market Data Tables and 27 Figures spread through 176 Pages and in-depth TOC on Global Eczema Therapeutics Market, by Treatment (Corticosteroids, Emollients/Moisturizers, Antihistamines, Calcineurin inhibitors, Antibiotics, Immunomodulators, and Interleukin inhibitors), by Distribution Channel (Hospital and Clinics, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the eczema therapeutics market, click the link below:

https://www.coherentmarketinsights.com/market-insight/eczema-therapeutics-market-4630

Increasing prevalence of atopic dermatitis globally is expected to drive the growth of the global eczema therapeutics market, over the forecast period. For instance, according to the article published in the Allergy and Asthma Network, in 2019, globally, 15-20% of the children are suffering from atopic dermatitis and 1-3% of the adults are currently suffering from atopic dermatitis or eczema.

Key Takeaways of the Eczema Therapeutics Market:

• The global eczema therapeutics market is expected to exhibit a CAGR of 11.1% over the forecast period (2021-2028), owing to growth in potential markets, especially in Europe. While North America region accounted for the major market share.
• Market players are involved in presenting their research at the conference. On April 23, 2021, Regeneron Pharmaceuticals, Inc., presented the new analyses of Dupixent (dupilumab) in patients as young as 6 years with moderate-to-severe atopic dermatitis, at the American Academy of Dermatology Annual Meeting and at the 20th European Society for Pediatric Dermatology Annual Meeting.
• Some of the major players operating in the global eczema therapeutics market include Sanofi S.A., Encore Dermatology Inc, AbbieVie Inc., F. Hoffmann-La Roche AG, Novartis AG, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Anacor Pharmaceuticals Inc., Meda AB, GlaxoSmithKline plc, AstraZeneca plc, and Pfizer Inc.